AI Stock Analysis - Crinetics Pharmaceuticals (CRNX)
Analysis generated July 15, 2025.
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Positioned within a niche but critical sector of the pharma industry, Crinetics leverages scientific expertise and innovative approaches to tackle medical conditions lacking effective treatment options. The company's pipeline includes small-molecule drugs aimed at treating disorders such as acromegaly, neuroendocrine tumors, and congenital adrenal hyperplasia.
Stock Alerts - Crinetics Pharmaceuticals (CRNX)
 |
Crinetics Pharmaceuticals | May 8 Price is down by -9.4% in the last 24h. |
|
Crinetics Pharmaceuticals | April 11 Insider Alert: Knight Jeff E. is selling shares |
|
Crinetics Pharmaceuticals | March 31 Price is up by 6.2% in the last 24h. |
|
Crinetics Pharmaceuticals | March 27 Price is down by -6.1% in the last 24h. |
Download our app on iOS or Android to get future alerts delivered in real-time.
Alternative Data for Crinetics Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 36 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 13,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 10 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,262 | Sign up | Sign up | Sign up |
| Instagram Followers | 178 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 10 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,453 | Sign up | Sign up | Sign up |
| X Followers | 1,071 | Sign up | Sign up | Sign up |
| X Mentions | 24 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 75 | Sign up | Sign up | Sign up |
| Linkedin Employees | 602 | Sign up | Sign up | Sign up |
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors.
| Price | $37.48 |
| Target Price | Sign up |
| Volume | 4,707,630 |
| Market Cap | $3.89B |
| Year Range | $33.67 - $56.43 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma StockMay 2 - Yahoo Entertainment |
Crinetics Pharmaceuticals (CRNX) is One of the Best Biotech Stocks to Buy, Here is WhyApril 29 - Yahoo Entertainment |
|
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in AdultsApril 27 - GlobeNewswire |
|
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026April 8 - GlobeNewswire |
|
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in AcromegalyMarch 26 - GlobeNewswire |
|
Crinetics Pharmaceuticals Q4 Earnings Call HighlightsFebruary 26 - Yahoo Entertainment |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | 11M | 200,000 | 11M | -128M | -140M | -1.230 |
| Q4 '25 | 6.2M | -460,000 | 6.2M | -123M | -133M | -1.290 |
| Q3 '25 | 140,000 | 90M | 140,000 | -130M | -142M | -1.380 |
| Q2 '25 | 1M | 960,000 | 1M | -116M | -128M | -1.230 |
| Q1 '25 | 360,000 | 0 | 360,000 | -97M | -110M | -1.040 |
Insider Transactions View All
| Knight Jeff E. filed to sell 105,289 shares at $40.1. April 10 '26 |
| Struthers Richard Scott filed to sell 404,778 shares at $37.8. March 18 '26 |
| Betz Stephen F. filed to sell 137,101 shares at $37.8. March 18 '26 |
| Betz Stephen F. filed to sell 141,342 shares at $37.1. March 18 '26 |
| Knight Jeff E. filed to sell 112,018 shares at $37.8. March 18 '26 |
Similar companies
Read more about Crinetics Pharmaceuticals (CRNX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Crinetics Pharmaceuticals
The Market Cap of Crinetics Pharmaceuticals is $3.89B.
Currently, the price of one share of Crinetics Pharmaceuticals stock is $37.48.
The CRNX stock price chart above provides a comprehensive visual representation of Crinetics Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crinetics Pharmaceuticals shares. Our platform offers an up-to-date CRNX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Crinetics Pharmaceuticals (CRNX) does not offer dividends to its shareholders. Investors interested in Crinetics Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Crinetics Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
